




**Supplementary Figure 1. No significant change in the body weight of mice treated with dinaciclib and/or anti-PD-1.** Mice bearing (A) MC38 (n=12), (B) CT26 (n=10) and (C) MB49 (n=10) tumors were treated with dinaciclib and anti-PD-1 alone or in combination. Dinaciclib (10 mg/kg) or vehicle control (2 Hydroxypropyl)- $\beta$ -cyclodextrin (HP $\beta$ CD) was administered intraperitoneally (i.p.) in 2 doses, 2 hours apart on days 0, 4, 8, and 12. Anti-PD-1 or isotype control (mIgG1) mAb was administered i.p. at 5 mg/kg on days 0, 4, 8 and 12. Body weight was assessed every 4-5 days and represented as percentage body weight change, mean  $\pm$  SEM.



**Supplementary Figure 2. Dinaciclib and anti-PD-1 combination therapy increases CD8<sup>+</sup> T cell infiltration and dendritic cell activation in the tumor.** Mice with established MC38 and MB49 tumors were treated with dinaciclib and/or anti-PD-1 mAb as described earlier. Tumors were isolated on day 14 and immune cells were analyzed by flow cytometry (n=5 mice per group). Shown are scatter plots for the number of tumor-infiltrating CD8<sup>+</sup>, CD4<sup>+</sup> T cells and CD11c<sup>+</sup> dendritic cells in (A, B) MC38 and (C, D) and MB49 tumors. Also shown is the activation status of these populations as measured by %CD69<sup>+</sup> CD4 and CD8 T cells (A, in MC38 and C, in MB49 tumor model) or MHC II, CD80, and CD86 mean fluorescence intensity (MFI) on DCs (B, in MC38 and D, in MB49). Statistically significant differences between groups are indicated with asterisks: \*\*\*P < 0.001; \*\*P < 0.01; \*P < 0.05.




**Supplementary Figure 3. No effect of dinaciclib treatment on splenic T cells.** Mice with established CT26 tumors were treated with dinaciclib and anti-PD-1 mAb as described earlier. Spleens were isolated on day 14 and immune cells were analyzed by flow cytometry (n=5 mice per group). Shown are the percentages of (A) CD8<sup>+</sup> T cells and (B) CD4<sup>+</sup> T cells. Also shown is the activation status of these populations as measured by %CD69<sup>+</sup> CD4 and CD8 T cells (C, D) Statistically significant differences between groups are indicated with asterisks: \*\*\*P < 0.001; \*\*P < 0.01.




- Isotype+Vehicle ■ Dinaciclib+Isotype ▲ Anti-PD-1+Vehicle ▼ Dinaciclib+Anti-PD-1


**Supplementary Figure 4. Dinaciclib and anti-PD-1 combination therapy increases tumor infiltrating T cell function.** Mice with established CT26 tumors were treated with dinaciclib and/or anti-PD-1 mAb as described earlier. TILs were isolated from dissociated tumors using density gradient centrifugation. For the detection of intracellular cytokines, harvested TILs were stimulated with PMA and ionomycin in presence of brefeldin A for 4h before staining. Shown are the percentages of (A) IFN $\gamma^+$ , (B) TNF $\alpha^+$  and (C) granzyme-B $^+$  CD4 $^+$  T cells (n=5 mice per group). Statistically significant differences between groups are indicated with asterisks: \*\*\*P < 0.001; \*\*P < 0.01; \*P < 0.05.





**Supplementary Figure 5. Dinaciclib induces immunogenic cancer cell death *in vivo* and *in vitro*.** (A-C) MC38 and MB49 cells were treated *in vitro* with 1 μM dinaciclib for 24h. Graphical data showing (A) percentage of tumor cell apoptosis, (B) HMGB1 release in culture supernatant and (C) expression of calreticulin on the tumor cell surface. (D) To check *in vivo* calreticulin expression, mice with established MC38 tumors were treated with dinaciclib (10mg/kg, 2 doses, 2h apart) for two consecutive days. 24h after the last dose, calreticulin expression on live CD45<sup>-</sup> tumor cells (n=3) was assessed by flow cytometry. Statistically significant differences between groups are indicated with asterisks: \*\*\*P < 0.001; \*\*P < 0.01; \*P < 0.05.



**Supplementary Figure 6. Immunogenic nature of dinaciclib is comparable to known ICD-inducer mitoxantrone.** CT26 cells were treated *in vitro* with 1µM dinaciclib or mitoxantrone. After 24h, (A) tumor cell apoptosis and (B) HMGB1 release into the culture supernatant were measured by caspase activity and ELISA, respectively. To detect phagocytosis, DiO-labeled CT26 cells were treated with 1µM of dinaciclib or mitoxantrone for 24h. Then cells were co-cultured with bone marrow derived dendritic cells for additional 24h. (C) Tumor cell phagocytosis by DCs is shown as the percent of double positive cells (DiO/tumor cell+ CD11c/dendritic cell+) using flow cytometry. Statistically significant differences between treatment groups and corresponding control groups are indicated with asterisks: \*\*\*P < 0.001; \*\*P < 0.01; \*P < 0.05.




**Supplementary Figure 7. Dinaciclib treatment enhances processing and presentation of tumor antigens by DCs.** MC38-OVA cells were treated with the indicated concentrations of dinaciclib for 24h, and then co-cultured with bone marrow-derived dendritic cells for an additional 24h. Expression of (A) MHCII, (B) CD86, (C) CD80 and (D) OVA peptide SIINFEKL bound to H-2K<sup>b</sup> on CD11c<sup>+</sup> dendritic cells were measured by flow cytometry. Data represents mean value  $\pm$  SEM of replicates of one representative experiment. \*\* indicates  $p < 0.01$ , for comparison between individual dinaciclib dose group and the untreated group (0  $\mu$ M).

**A****B**

**Supplementary Figure 8. Dinaciclib induces PD-L1 expression on tumor cells *in vitro*.**

CT26 cells were treated *in vitro* with dinaciclib at the indicated concentrations for 24h either continuously (A) or washing and replacing medium after 2h (B). Shown is the expression of PD-L1 on live tumor cells after 24h in both the treatment conditions. Data represents mean value  $\pm$  SEM of triplicates of one representative experiment. \*\* indicates  $p < 0.01$ , and \* indicates  $p < 0.05$  for comparison between individual dinaciclib dose group and the untreated group (0  $\mu\text{M}$ ).



**Supplementary Figure 9. Differential effect of dinaciclib on T cells versus tumor cells.**

Mouse splenic T cells (stimulated 2 days with 10ug/ml plate bound anti-CD3 and 1ug/ml soluble anti-CD28) and CT26 tumor cells were treated with different concentrations of dinaciclib as indicated. After 2h of treatment medium was replaced and cells were cultured for another 24h. Comparative data showing percentage of T cell and tumor cell (A) apoptosis and (B) proliferation. Data represents mean value  $\pm$  SEM of 2 replicates of one representative experiment. \*\*\* indicates  $p < 0.001$  for comparison between T cells and tumor cells.

Supplementary Table-1: List of type I interferon response genes in CT26, MB49 and MC38 tumor cells after <i>in vitro</i> dinaciclib treatment for 24h or 2h pulse.			CT26				MB49				MC38			
			2h pulse		24h		2h pulse		24h		2h pulse		24h	
			Gene Symbol	Description*	Assay ID**	FC (Log10)	p value	FC (Log10)	p value	FC (Log10)	p value	FC (Log10)	p value	FC (Log10)
<i>Bst2</i>	bone marrow stromal cell antigen 2	Mm01609165_g1	0.763955	2.33E-05	0.734152	6.11E-06	1.310436	8.58E-08	1.4149383	8.88E-06	0.716795	0.000228	0.9393549	0.000186
<i>Cav1</i>	caveolin 1, caveolae protein	Mm00483057_m1	0.580232	0.002681	0.529059	0.000201	1.080793	4.62E-06	1.2007396	1.77E-06	0.432755	0.000314	0.7482968	0.000228
<i>Jak1</i>	Janus kinase 1	Mm00600614_m1	0.571424	0.001836	0.464512	0.000848	1.028914	1.17E-05	1.133685	7.27E-05	0.418275	0.000113	0.7327187	0.001383
<i>Ifnar2</i>	interferon (alpha and beta) receptor 2	Mm00494916_m1	0.49796	0.003265	0.516174	9.15E-05	0.778706	9.91E-06	1.026764	9.68E-06	0.352564	0.000649	0.5918989	0.000513
<i>Ifitm2</i>	interferon induced transmembrane protein 2	Mm00850080_g1	0.420506	0.002498	0.447785	0.000807	1.059991	6.01E-06	1.206264	5.2E-05	0.532804	0.000226	0.7835555	0.000207
<i>H2-D1</i>	histocompatibility 2, D region locus 1	Mm01612937_g1	0.818326	0.004481	0.729136	0.003679	1.089563	0.000216	1.2346506	0.000272	0.86394	7.58E-05	0.7656901	0.00287
<i>Ifitm3</i>	interferon induced transmembrane protein 3	Mm00847057_s1	0.66015	0.000214	0.618676	0.000439	1.094982	1.84E-06	1.3254928	1.47E-05	0.677895	0.000216	0.9852393	9.47E-05
<i>Timp1</i>	tissue inhibitor of metalloproteinase 1	Mm00441818_m1	0.707708	0.002115	0.729039	4.71E-05	1.057466	6.98E-07	1.2375523	5.81E-07	0.711395	2.24E-05	0.9280839	0.000122
<i>H2-T23</i>	histocompatibility 2, T region locus 23	Mm00439246_g1	0.541593	0.000762	0.549684	4.67E-05	0.961003	8.85E-06	1.0839764	1.87E-05	0.279781	0.01043	0.4793494	0.036767
<i>Isg20</i>	interferon stimulated exonuclease gene 20	Mm00469585_m1	0.478249	0.008396	0.382366	0.000246	0.813537	5.1E-05	1.0364373	5.8E-05	0.270757	0.005767	0.4978722	0.000406
<i>Myd88</i>	myeloid differentiation primary response gene 88	Mm00440338_m1	0.326668	0.021545	-0.020267	0.741092	0.697213	1.45E-05	0.9040395	0.002777	0.415531	0.049867	0.6618325	0.000734
<i>Samhd1</i>	SAM domain and HD domain, 1	Mm01250767_m1	0.367883	0.007524	0.218789	0.013189	0.812825	2.08E-07	0.9967069	3.77E-05	0.496005	7.38E-05	0.6428532	0.000424
<i>Ccl5</i>	C-C motif chemokine ligand 5	Mm01302428_m1	0.610901	0.000897	0.553805	9.93E-06	0.993588	0.016428	0.3371414	0.600969	0.450242	0.003794	0.7466995	0.000283
<i>Cxcl10</i>	chemokine (C-X-C motif) ligand 10	Mm00445235_m1	0.404564	0.006321	0.681325	2.3E-05	0.281609	0.199449	0.4329817	0.029715	1.041201	4.08E-05	1.1250865	0.000108
<i>Oas1a</i>	2'-5' oligoadenylate synthetase 1A	Mm00836412_m1	0.438259	0.023841	0.328233	0.001288	0.830613	0.001417	0.5616247	0.436581	0.152866	0.66911	0.3247195	0.488865
<i>Ccl2</i>	chemokine (C-C motif) ligand 2	Mm00441242_m1	0.905974	3.04E-05	-0.506035	5.65E-05	1.049307	7.81E-05	1.1823384	1.08E-05	0.165045	0.074404	0.4259168	0.001802
<i>Nmi</i>	N-myc (and STAT) interactor	Mm00803857_m1	0.269081	0.024749	0.12839	0.02541	0.763066	7.06E-05	0.756071	0.001381	0.209154	0.003151	0.3735657	0.000102
<i>Irf204</i>	interferon activated gene 204	Mm00492602_m1	-0.11256	0.331261	-0.1444	0.153334	0.563055	0.000102	0.6447386	0.011694	0.029595	0.599221	0.3429896	0.004435
<i>Gbp2</i>	guanylate binding protein 2	Mm00494576_g1	0.128455	0.04501	-0.002458	0.984388	0.576796	0.000386	0.8579964	0.000507	0.061413	0.430052	0.3259058	0.019813
<i>Stat1</i>	signal transducer and activator of transcription 1	Mm00439518_m1	0.26775	0.043464	0.132948	0.052905	0.992676	0.000163	1.0461073	7.4E-05	0.35255	0.000164	0.3554357	0.024454
<i>H2-K1</i>	histocompatibility 2, K1, K region	Mm01612247_mH	0		0		1.338949	9.26E-06	1.4418496	3.11E-06	0.734028	7.28E-05	0.9170778	6E-05
<i>Eif2ak2</i>	eukaryotic translation initiation factor 2-alpha kinase 2	Mm01235646_g1	-0.237061	0.112029	-0.14521	0.01142	0.327207	0.018	0.5797877	0.005019	-0.130719	0.1198	0.2738306	0.029064
<i>Irf35</i>	interferon-induced protein 35	Mm01260550_g1	-0.050101	0.551848	-0.07574	0.452965	0.473007	0.011774	0.7855224	2.64E-06	-0.046753	0.69575	0.2082568	0.001729
<i>Casp1</i>	caspase 1	Mm00438023_m1	0.194375	0.050137	0.228331	0.002885	0.729404	0.001768	0.8543297	0.000504	0.088548	0.233517	0.1504504	0.118768
<i>Stat3</i>	signal transducer and activator of transcription 3	Mm00456961_m1	-0.047033	0.576104	-0.168013	0.125979	0.564198	0.008918	0.545612	0.005184	-0.163982	0.013256	-0.15127	0.103872
<i>H2-M3</i>	histocompatibility 2, M region locus 3	Mm00469263_m1	0.35222	0.003	0.355273	0.000443	0.972125	3.57E-05	1.114201	6.53E-06	0.045212	0.491865	0.1485955	0.515518
<i>Ddx58</i>	DEAD (Asp-Glu-Ala-Asp) box polypeptide 58	Mm00554529_m1	-0.182799	0.028513	-0.3112	0.026215	0.473682	0.003593	0.5467006	0.000329	-0.05597	0.118676	0.2453494	0.001788
<i>Cd80</i>	CD80 antigen	Mm00711660_m1	0.318593	0.101868	-0.096551	0.484221	0.740617	0.001817	0.5083231	0.132056	0		0	
<i>H2-T10</i>	histocompatibility 2, T region locus 10	Mm02393403_m1	0		0		0.002108	0.997356	0.4634514	0.001402	-0.025278	0.878392	0.3620287	0.045353
<i>Ifnar1</i>	interferon (alpha and beta) receptor 1	Mm00439544_m1	0.1964	0.067404	-0.248208	0.114557	0.19359	0.009492	0.3922773	0.044032	-0.146798	0.043895	0.1956917	0.166937
<i>Irf30</i>	interferon gamma inducible protein 30	Mm00499131_m1	-0.061683	0.028214	-0.444396	5.39E-05	0.298366	0.007392	0.3507517	0.002402	-0.169193	0.029318	0.012237	0.888606
<i>Irfb1</i>	interferon beta 1, fibroblast	Mm00439546_s1	0.168314	0.799686	0.866583	3.4E-05	0.464979	0.373901	0		0.738042	0.125731	0.4751427	0.373901
<i>Irfna2</i>	interferon alpha 2	Mm00833961_s1	0.397746	0.373901	0.466131	0.373901	0		0		0.968374	0.01073	0.5413593	0.373901
<i>Irf7</i>	interferon regulatory factor 7	Mm00516788_m1	0.881616	0.000733	0.718153	6.88E-05	0.272049	0.6262	-0.755137	5.4E-05	-0.763499	0.045537	-0.587871	0.253865
<i>Ifitm1</i>	interferon induced transmembrane protein 1	Mm00850040_g1	0.751666	0.004114	0.707069	6.63E-06	0.457269	0.529728	-0.189649	0.290364	0.165568	0.142561	0.3763174	0.098479
<i>Oas1g</i>	2'-5' oligoadenylate synthetase 1G	Mm01730198_m1	0.646922	0.00187	0.52644	0.000323	0.153117	0.777211	0.3175188	0.658619	0.077977	0.693966	-0.099429	0.117109
<i>Traf3</i>	TNF receptor-associated factor 3	Mm00495752_m1	0.564753	0.006566	0.340842	0.010382	0.943515	0.124575	0		0.277597	0.012298	0.5338484	0.000318
<i>Ptpn5</i>	protein tyrosine phosphatase, non-receptor type 5	Mm00479066_m1	0.474194	0.020688	-0.303787	0.448917	0.17308	0.72076	-0.260109	0.587423	0.298908	0.378572	-0.135206	0.775495

FC: Fold change (Log10); \*Source: <https://www.ncbi.nlm.nih.gov/gene/>; \*\*Source: Applied Biosystems (Thermo Fisher Scientific)

**Supplementary Table 2: List of upregulated genes in whole MC38 tumor isolated from mice 24 hours after treatment with dinaciclib and anti-PD-1 alone or in combination.**

<b>Dinaciclib</b>			
<b>Gene Symbol</b>	<b>Description*</b>	<b>FC (Log10)</b>	<b>p value</b>
<i>RP24-492O4.5</i>	<i>retinitis pigmentosa 24 (X-linked recessive)</i>	1.221	5.87E-03
<i>D630023F18Rik</i>	RIKEN cDNA D630023F18 gene	1.177	1.03E-06
<i>Ifnb1</i>	interferon beta 1, fibroblast	0.982	5.33E-03
<i>Speer3</i>	spermatogenesis associated glutamate (E)-rich protein 3	0.923	6.79E-03
<i>Gm7970</i>	predicted gene 7970	0.885	6.70E-03
<i>Gm5447</i>	predicted gene 5447	0.871	4.55E-03
<i>Olfr1193</i>	olfactory receptor 1193	0.865	7.36E-03
<i>Tacr2</i>	tachykinin receptor 2	0.848	9.31E-03
<i>Pdzd9</i>	PDZ domain containing 9	0.842	3.71E-03
<i>Ankmy1</i>	ankyrin repeat and MYND domain containing 1	0.829	6.09E-03
<i>Adam1b</i>	a disintegrin and metallopeptidase domain 1b	0.736	4.39E-03
<i>Oas1d</i>	2'-5' oligoadenylate synthetase 1D	0.634	7.77E-03
<i>Grid1</i>	glutamate receptor, ionotropic, delta 1	0.623	2.99E-03
<i>Teddm1b</i>	transmembrane epididymal protein 1B	0.603	7.43E-03
<i>Igsf21</i>	immunoglobulin superfamily, member 21	0.59	5.39E-03
<i>F11</i>	coagulation factor XI	0.587	8.47E-03
<i>Plekhb1</i>	pleckstrin homology domain containing, family B (evectins) member 1	0.558	6.89E-03
<i>Tshb</i>	thyroid stimulating hormone, beta subunit	0.523	7.62E-03
<i>Aldh8a1</i>	aldehyde dehydrogenase 8 family, member A1	0.504	3.99E-03
<i>Gm5615</i>	predicted gene 5615	0.491	3.98E-03
<i>Ccdc81</i>	coiled-coil domain containing 81	0.477	4.24E-03
<i>Pax5</i>	paired box 5	0.468	1.42E-03
<i>Dcdc2c</i>	doublecortin domain containing 2C	0.454	4.46E-03
<i>Rimbp3</i>	RIMS binding protein 3	0.432	1.47E-04
<i>Oas3</i>	2'-5' oligoadenylate synthetase 3	0.428	2.53E-03
<i>Iifi44</i>	interferon-induced protein 44	0.423	6.09E-04
<i>Syng4</i>	synaptogyrin 4	0.392	1.58E-05
<i>Il1rl1</i>	interleukin 1 receptor-like 1	0.391	2.50E-04
<i>Rsad2</i>	radical S-adenosyl methionine domain containing 2	0.391	2.03E-03
<i>Oas1l</i>	2'-5' oligoadenylate synthetase-like 1	0.389	1.45E-03
<i>Ifit3b</i>	interferon-induced protein with tetratricopeptide repeats 3B	0.383	7.83E-03
<i>Prl2c3</i>	prolactin family 2, subfamily c, member 3	0.38	8.22E-03
<i>Slc47a1</i>	solute carrier family 47, member 1	0.377	1.84E-03
<i>Prl2c5</i>	prolactin family 2, subfamily c, member 5	0.369	2.33E-03
<i>Cmpk2</i>	cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial	0.358	4.79E-03
<i>Ifit3</i>	interferon-induced protein with tetratricopeptide repeats 3	0.358	8.24E-03
<i>Oas1g</i>	2'-5' oligoadenylate synthetase 1G	0.357	6.16E-04
<i>Oas1a</i>	2'-5' oligoadenylate synthetase 1A	0.335	5.12E-04
<i>Isg15</i>	ISG15 ubiquitin-like modifier	0.331	2.15E-03
<i>Apol9a</i>	apolipoprotein L 9a	0.329	1.56E-04
<i>Usp18</i>	ubiquitin specific peptidase 18	0.329	7.56E-03
<i>Lgr6</i>	leucine-rich repeat-containing G protein-coupled receptor 6	0.326	1.55E-03
<i>Dlk2</i>	delta-like 2 homolog (Drosophila)	0.325	3.43E-03
<i>Nxf7</i>	nuclear RNA export factor 7	0.324	8.45E-03
<i>Gm6904</i>	predicted gene 6904	0.322	3.58E-03
<i>Ces2e</i>	carboxylesterase 2E	0.322	3.04E-03
<i>Phf11d</i>	PHD finger protein 11D	0.321	1.73E-03
<i>Phf11a</i>	PHD finger protein 11A	0.307	8.52E-03
<i>Apol9b</i>	apolipoprotein L 9b	0.303	6.80E-04
<i>Ddx60</i>	DEAD (Asp-Glu-Ala-Asp) box polypeptide 60	0.301	9.67E-04
<b>Anti-PD-1</b>			
<b>Gene Symbol</b>	<b>Description*</b>	<b>FC (Log10)</b>	<b>p value</b>
<i>Ijne</i>	interferon epsilon	0.958	4.51E-03
<i>Slc27a5</i>	solute carrier family 27 (fatty acid transporter), member 5	0.849	9.48E-03
<i>Cartpt</i>	CART prepropeptide	0.834	5.99E-03
<i>Spata17</i>	spermatogenesis associated 17	0.802	7.45E-03
<i>Ppil6</i>	peptidylprolyl isomerase (cyclophilin)-like 6	0.793	5.13E-03
<i>Sun3</i>	Sad1 and UNC84 domain containing 3	0.768	3.06E-03
<i>Fam163a</i>	family with sequence similarity 163, member A	0.664	2.03E-04
<i>Tm4sf4</i>	transmembrane 4 superfamily member 4	0.587	3.96E-03

<i>Nkx2-3</i>	NK2 homeobox 3	0.553	5.03E-03
<i>Pnoc</i>	prepronociceptin	0.536	5.47E-03
<i>Lrrc38</i>	leucine rich repeat containing 38	0.527	5.55E-03
<i>Fcrl6</i>	Fc receptor-like 6	0.481	8.43E-03
<i>Gbp6</i>	guanylate binding protein 6	0.45	9.11E-03
<i>Gzmc</i>	granzyme C	0.438	5.21E-03
<i>Tmc1</i>	transmembrane channel-like gene family 1	0.427	5.61E-03
<i>Trpm1</i>	transient receptor potential cation channel, subfamily M, member 1	0.421	5.85E-03
<i>Gzmb</i>	granzyme B	0.406	6.43E-03
<i>Gbp10</i>	guanylate-binding protein 10	0.391	7.78E-03
<i>Dyrk4</i>	dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 4	0.372	8.79E-04
<i>S100a3</i>	S100 calcium binding protein A3	0.371	8.66E-03
<i>Tgtp1</i>	T cell specific GTPase 1	0.342	6.97E-03
<i>Serpina3f</i>	serine (or cysteine) peptidase inhibitor, clade A, member 3F	0.337	7.24E-03
<i>Apol6</i>	apolipoprotein L 6	0.334	6.83E-03
<i>Gm12185</i>	predicted gene 12185	0.331	4.85E-03
<i>Igtp</i>	interferon gamma induced GTPase	0.331	7.08E-03
<i>Ubd</i>	ubiquitin D	0.314	2.50E-03
<i>Batf2</i>	basic leucine zipper transcription factor, ATF-like 2	0.313	7.38E-03
<i>Cst7</i>	cystatin F (leukocystatin)	0.312	6.38E-03
<b>Anti-PD-1+Dinaciclib</b>			
<b>Gene Symbol</b>	<b>Description*</b>	<b>FC (Log10)</b>	<b>p value</b>
<i>Mup19</i>	major urinary protein 19	1.54	5.04E-03
<i>Myf6</i>	myogenic factor 6	1.468	4.97E-03
<i>Prm1</i>	protamine 1	1.384	4.64E-03
<i>Gm7325</i>	predicted gene 7325	1.269	1.26E-03
<i>Hspb3</i>	heat shock protein 3	1.232	6.74E-03
<i>Gck</i>	glucokinase	1.224	5.83E-03
<i>Rasd2</i>	radical S-adenosyl methionine domain containing 2	1.216	5.22E-03
<i>Gm3448</i>	predicted gene 3448	1.203	4.38E-03
<i>Ifnb1</i>	interferon beta 1, fibroblast	1.151	5.20E-03
<i>Myod1</i>	myogenic differentiation 1	1.146	6.82E-03
<i>Gm13305</i>	predicted gene 13305	1.138	2.73E-03
<i>Pdk4</i>	pyruvate dehydrogenase kinase, isoenzyme 4	1.118	4.24E-03
<i>Krt20</i>	keratin 20	1.116	5.17E-04
<i>Trim63</i>	tripartite motif-containing 63	1.082	3.86E-03
<i>1700015F17Rik</i>	RIKEN cDNA 1700015F17 gene	1.041	7.35E-03
<i>2300005B03Rik</i>	RIKEN cDNA 2300005B03 gene	1.02	4.76E-03
<i>Myog</i>	myogenin	1.019	4.79E-03
<i>Nmrk2</i>	nicotinamide riboside kinase 2	1.019	8.44E-03
<i>Khdc1a</i>	KH domain containing 1A	1.011	2.55E-04
<i>Sgcg</i>	sarcoglycan, gamma (dystrophin-associated glycoprotein)	1.005	5.22E-03
<i>Krt24</i>	keratin 24	0.997	7.55E-03
<i>Hspb7</i>	heat shock protein family, member 7 (cardiovascular)	0.997	8.09E-03
<i>Rbm24</i>	RNA binding motif protein 24	0.988	8.26E-03
<i>Ninj2</i>	ninjurin 2	0.976	3.93E-03
<i>Abcb11</i>	ATP-binding cassette, sub-family B (MDR/TAP), member 11	0.975	2.00E-04
<i>D630023F18Rik</i>	RIKEN cDNA D630023F18 gene	0.974	2.50E-06
<i>2310007B03Rik</i>	RIKEN cDNA 2310007B03 gene	0.963	7.63E-07
<i>Gm19345</i>	predicted gene, 19345	0.952	7.71E-03
<i>Gm21655</i>	predicted gene, 21655	0.95	4.31E-03
<i>1700014D04Rik</i>	RIKEN cDNA 1700014D04 gene	0.949	9.38E-04
<i>Msln</i>	mesothelin	0.941	4.80E-03
<i>Fabp12</i>	fatty acid binding protein 12	0.935	5.63E-03
<i>Mylk2</i>	myosin light chain kinase 2	0.925	6.83E-03
<i>Eef1a2</i>	eukaryotic translation elongation factor 1 alpha 2	0.915	9.52E-03
<i>Mybph</i>	myosin binding protein H	0.912	5.75E-03
<i>Hrc</i>	histidine rich calcium binding protein	0.908	3.44E-03
<i>Tmod4</i>	tropomodulin 4	0.9	2.79E-03
<i>Tnnt3</i>	troponin T3, skeletal, fast	0.894	9.93E-03
<i>Gzmf</i>	granzyme F	0.89	9.19E-03
<i>Myo18b</i>	myosin XVIIIb	0.89	4.68E-03
<i>Smtnl1</i>	smoothelin-like 1	0.882	9.68E-03
<i>Gm15401</i>	predicted gene 15401	0.882	6.67E-03

<i>Pdlim3</i>	PDZ and LIM domain 3	0.881	8.00E-03
<i>Myh4</i>	myosin, heavy polypeptide 4, skeletal muscle	0.878	8.60E-03
<i>Rhox8</i>	reproductive homeobox 8	0.85	5.13E-03
<i>Asb16</i>	ankyrin repeat and SOCS box-containing 16	0.847	7.55E-04
<i>Pygm</i>	glycogen phosphorylase, muscle associated	0.847	9.83E-03
<i>Mybpc1</i>	myosin binding protein C, slow-type	0.842	8.44E-03
<i>Ano5</i>	anoctamin 5	0.817	1.90E-03
<i>Ddo</i>	D-aspartate oxidase	0.806	4.12E-03
<i>Zfp641</i>	zinc finger protein 641	0.805	6.05E-03
<i>Klhl41</i>	kelch-like 41	0.797	8.83E-03
<i>Cmya5</i>	cardiomyopathy associated 5	0.79	4.47E-03
<i>Neb</i>	nebulin	0.786	8.92E-03
<i>Dusp27</i>	dual specificity phosphatase 27 (putative)	0.784	4.17E-03
<i>Nrap</i>	nebulin-related anchoring protein	0.782	6.38E-03
<i>Nxf2</i>	nuclear RNA export factor 2	0.779	6.22E-03
<i>Coro6</i>	coronin 6	0.773	7.06E-03
<i>Des</i>	desmin	0.767	8.46E-03
<i>Hspb1</i>	heat shock protein 1	0.756	6.35E-03
<i>Ryr1</i>	ryanodine receptor 1, skeletal muscle	0.756	5.99E-03
<i>Mboat4</i>	membrane bound O-acyltransferase domain containing 4	0.742	4.70E-03
<i>Vmn1r42</i>	vomer nasal 1 receptor 42	0.74	4.15E-03
<i>Nos1</i>	nitric oxide synthase 1, neuronal	0.737	4.08E-03
<i>Cryab</i>	crystallin, alpha B	0.734	6.65E-03
<i>Angptl4</i>	angiopoietin-like 4	0.72	4.04E-04
<i>Sgca</i>	sarcoglycan, alpha (dystrophin-associated glycoprotein)	0.704	9.29E-03
<i>Cap2</i>	CAP, adenylate cyclase-associated protein, 2 (yeast)	0.704	6.52E-03
<i>Dynap</i>	dynactin associated protein	0.685	2.83E-04
<i>4930548H24Rik</i>	RIKEN cDNA 4930548H24 gene	0.677	8.27E-03
<i>Fbxo40</i>	F-box protein 40	0.666	9.72E-03
<i>Hspb2</i>	heat shock protein 2	0.665	9.96E-03
<i>Prl2c3</i>	prolactin family 2, subfamily c, member 3	0.653	2.92E-04
<i>Klhl30</i>	kelch-like 30	0.646	9.79E-03
<i>Arg1</i>	arginase, liver	0.642	4.42E-03
<i>Tmem182</i>	transmembrane protein 182	0.628	5.00E-03
<i>Wfdc3</i>	WAP four-disulfide core domain 3	0.579	6.77E-03
<i>Myh7</i>	myosin, heavy polypeptide 7, cardiac muscle, beta	0.578	1.73E-03
<i>Ifit1bl1</i>	interferon induced protein with tetratricopeptide repeats 1B like 1	0.574	1.99E-06
<i>Ffar1</i>	free fatty acid receptor 1	0.572	2.50E-03
<i>Oasl1</i>	2'-5' oligoadenylate synthetase-like 1	0.568	1.48E-05
<i>Gm5415</i>	predicted gene 5415	0.567	2.36E-04
<i>Rsad2</i>	radical S-adenosyl methionine domain containing 2	0.56	1.54E-06
<i>A530064D06Rik</i>	RIKEN cDNA A530064D06 gene	0.56	1.40E-04
<i>Stra6l</i>	STRA6-like	0.553	5.12E-04
<i>Htr2b</i>	5-hydroxytryptamine (serotonin) receptor 2B	0.549	3.28E-03
<i>Tnnt1</i>	troponin T1, skeletal, slow	0.549	4.95E-03
<i>Cdhr3</i>	cadherin-related family member 3	0.54	9.89E-03
<i>Ms4a4a</i>	membrane-spanning 4-domains, subfamily A, member 4A	0.538	4.62E-04
<i>Clca3a1</i>	chloride channel accessory 3A1	0.537	5.42E-04
<i>Gzmc</i>	granzyme C	0.535	7.68E-03
<i>Ifit3</i>	interferon-induced protein with tetratricopeptide repeats 3	0.533	9.26E-06
<i>Ifit3b</i>	interferon-induced protein with tetratricopeptide repeats 3B	0.524	8.42E-06
<i>Gzmb</i>	granzyme B	0.518	2.67E-03
<i>BC094916</i>	interferon activated gene 214	0.516	7.21E-04
<i>Tal2</i>	T cell acute lymphocytic leukemia 2	0.512	9.48E-03
<i>1700123I01Rik</i>	RIKEN cDNA 1700123I01 gene	0.508	7.94E-03
<i>Il21</i>	interleukin 21	0.504	3.79E-03
<i>Ttn</i>	titin	0.503	9.50E-03
<i>Prl2c5</i>	prolactin family 2, subfamily c, member 5	0.489	1.72E-04
<i>Il1rn</i>	interleukin 1 receptor antagonist	0.488	8.27E-03
<i>Ppbp</i>	pro-platelet basic protein	0.486	7.74E-03
<i>Cmpk2</i>	cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial	0.481	6.64E-06
<i>Il1rl1</i>	interleukin 1 receptor-like 1	0.48	3.40E-04
<i>Isg15</i>	ISG15 ubiquitin-like modifier	0.48	1.17E-05
<i>Il7r</i>	interleukin 7 receptor	0.478	4.85E-03

<i>Fam189a2</i>	family with sequence similarity 189, member A2	0.476	7.71E-03
<i>Oas3</i>	2'-5' oligoadenylate synthetase 3	0.476	1.70E-04
<i>Plin2</i>	perilipin 2	0.471	2.69E-04
<i>B430306N03Rik</i>	RIKEN cDNA B430306N03 gene	0.47	9.02E-04
<i>Slc9a2</i>	solute carrier family 9 (sodium/hydrogen exchanger), member 2	0.459	4.17E-04
<i>Clic5</i>	chloride intracellular channel 5	0.457	4.27E-03
<i>Ift1</i>	interferon-induced protein with tetratricopeptide repeats 1	0.449	1.33E-04
<i>Srgn</i>	serglycin	0.448	2.31E-03
<i>C5ar2</i>	complement component 5a receptor 2	0.448	4.94E-04
<i>Gm4955</i>	predicted gene 4955	0.446	1.27E-04
<i>Ksr2</i>	kinase suppressor of ras 2	0.442	1.91E-03
<i>Ms4a4c</i>	membrane-spanning 4-domains, subfamily A, member 4C	0.438	1.07E-04
<i>Il18bp</i>	interleukin 18 binding protein	0.436	1.10E-03
<i>Usp18</i>	ubiquitin specific peptidase 18	0.435	1.01E-04
<i>Oas1g</i>	2'-5' oligoadenylate synthetase 1G	0.434	4.35E-05
<i>Ifi44</i>	interferon-induced protein 44	0.433	2.84E-05
<i>Gprc5a</i>	G protein-coupled receptor, family C, group 5, member A	0.431	2.42E-04
<i>Gpr55</i>	G protein-coupled receptor 55	0.428	2.58E-03
<i>Slfm4</i>	schlafen 4	0.426	5.16E-04
<i>Rhbg</i>	Rhesus blood group-associated B glycoprotein	0.426	3.55E-03
<i>Spink2</i>	serine peptidase inhibitor, Kazal type 2	0.425	9.14E-03
<i>Apol9a</i>	apolipoprotein L 9a	0.419	1.52E-06
<i>Prl2c2</i>	prolactin family 2, subfamily c, member 2	0.411	2.95E-03
<i>Oas1a</i>	2'-5' oligoadenylate synthetase 1A	0.411	7.64E-06
<i>Fam195a</i>	family with sequence similarity 195, member A	0.41	2.54E-05
<i>Slfm1</i>	schlafen 1	0.409	1.30E-05
<i>Phf11a</i>	PHD finger protein 11A	0.409	7.42E-04
<i>Mx1</i>	MX dynamin-like GTPase 1	0.4	3.22E-04
<i>Oasl2</i>	2'-5' oligoadenylate synthetase-like 2	0.397	1.16E-05
<i>Adssl1</i>	adenylosuccinate synthetase like 1	0.395	3.98E-03
<i>Zdbf2</i>	zinc finger, DBF-type containing 2	0.394	1.81E-03
<i>Apol9b</i>	apolipoprotein L 9b	0.394	4.51E-07
<i>Myh3</i>	myosin, heavy polypeptide 3, skeletal muscle, embryonic	0.393	4.87E-03
<i>AA467197</i>	expressed sequence AA467197	0.393	2.45E-03
<i>Pyhin1</i>	pyrin and HIN domain family member 1	0.391	9.30E-05
<i>Irf7</i>	interferon regulatory factor 7	0.39	2.04E-04
<i>Phf11d</i>	PHD finger protein 11D	0.388	7.61E-06
<i>Abcc3</i>	ATP-binding cassette, sub-family C (CFTR/MRP), member 3	0.384	4.63E-04
<i>Dhx58</i>	DEXH (Asp-Glu-X-His) box polypeptide 58	0.384	5.47E-05
<i>Omp</i>	olfactory marker protein	0.383	9.69E-03
<i>Ocstamp</i>	osteoclast stimulatory transmembrane protein	0.378	1.61E-03
<i>Syngn4</i>	synaptogyrin 4	0.378	1.91E-03
<i>Pax5</i>	paired box 5	0.377	3.63E-03
<i>Ttl9</i>	tubulin tyrosine ligase-like family, member 9	0.376	2.18E-03
<i>Oas2</i>	2'-5' oligoadenylate synthetase 2	0.371	1.25E-04
<i>Slc37a2</i>	solute carrier family 37 (glycerol-3-phosphate transporter), member 2	0.371	3.74E-04
<i>Aldh1b1</i>	aldehyde dehydrogenase 1 family, member B1	0.37	3.67E-03
<i>Hsh2d</i>	hematopoietic SH2 domain containing	0.368	1.11E-03
<i>Ces2e</i>	carboxylesterase 2E	0.368	4.28E-03
<i>Cd22</i>	CD22 antigen	0.366	5.97E-03
<i>Ptger2</i>	prostaglandin E receptor 2 (subtype EP2)	0.365	3.35E-03
<i>Car7</i>	carbonic anhydrase 7	0.365	9.47E-03
<i>Nr1h3</i>	nuclear receptor subfamily 1, group H, member 3	0.364	9.94E-03
<i>Adh1</i>	alcohol dehydrogenase 1 (class I)	0.364	7.15E-03
<i>Lag3</i>	lymphocyte-activation gene 3	0.363	7.63E-03
<i>Gja8</i>	gap junction protein, alpha 8	0.361	6.91E-03
<i>Fcgr4</i>	Fc receptor, IgG, low affinity IV	0.357	6.06E-03
<i>Gm4841</i>	predicted gene 4841	0.357	2.75E-03
<i>Nkg7</i>	natural killer cell group 7 sequence	0.357	6.54E-03
<i>Guca1b</i>	guanylate cyclase activator 1B	0.356	1.97E-03
<i>DIK2</i>	delta-like 2 homolog (Drosophila) [Mus musculus	0.354	7.91E-03
<i>Gm5431</i>	predicted gene 5431	0.353	1.72E-04
<i>Tfec</i>	transcription factor EC	0.353	2.53E-03
<i>Dnah6</i>	dynein, axonemal, heavy chain 6	0.353	8.32E-03

<i>Csf2rb2</i>	colony stimulating factor 2 receptor, beta 2, low-affinity (granulocyte-macrophage)	0.351	3.02E-03
<i>Xaf1</i>	XIAP associated factor 1	0.349	4.15E-06
<i>Ms4a6d</i>	membrane-spanning 4-domains, subfamily A, member 6D	0.348	9.01E-04
<i>Ankrd1</i>	ankyrin repeat domain 1 (cardiac muscle)	0.348	6.73E-03
<i>Ankrd55</i>	ankyrin repeat domain 55	0.347	7.93E-03
<i>Bst2</i>	bone marrow stromal cell antigen 2	0.346	3.14E-06
<i>Fam110c</i>	family with sequence similarity 110, member C	0.345	3.60E-04
<i>AC132444.1</i>	-	0.345	4.04E-03
<i>Gm5150</i>	predicted gene 5150	0.343	1.35E-03
<i>Nrip3</i>	nuclear receptor interacting protein 3	0.343	9.26E-03
<i>Ccl5</i>	C-C motif chemokine ligand 5	0.342	9.88E-04
<i>Tmem220</i>	transmembrane protein 220	0.34	1.58E-03
<i>Hap1</i>	huntingtin-associated protein 1	0.34	7.06E-05
<i>Ifi35</i>	interferon-induced protein 35	0.339	4.03E-06
<i>Slc7a8</i>	solute carrier family 7 (cationic amino acid transporter, y+ system), member 8	0.339	3.20E-04
<i>Gpr171</i>	G protein-coupled receptor 171	0.338	2.70E-03
<i>Tbx21</i>	T-box 21	0.334	6.01E-04
<i>Tnfrsf11a</i>	tumor necrosis factor receptor superfamily, member 11a, NFKB activator	0.333	1.08E-03
<i>Zbp1</i>	Z-DNA binding protein 1	0.33	2.53E-05
<i>Igsf6</i>	immunoglobulin superfamily, member 6	0.33	5.63E-03
<i>Adap2</i>	ArfGAP with dual PH domains 2	0.329	7.39E-04
<i>Aldh3b1</i>	aldehyde dehydrogenase 3 family, member B1	0.327	4.98E-04
<i>Tnfrsf19</i>	tumor necrosis factor receptor superfamily, member 19	0.326	4.05E-03
<i>Acrbp</i>	proacrosin binding protein	0.324	4.02E-04
<i>Lgr6</i>	leucine-rich repeat-containing G protein-coupled receptor 6	0.322	2.25E-03
<i>Grrp1</i>	glycine/arginine rich protein 1	0.322	9.61E-03
<i>Pnma5</i>	paraneoplastic Ma antigen family member 5	0.322	6.85E-03
<i>Ribc1</i>	RIB43A domain with coiled-coils 1	0.322	7.65E-04
<i>Misp</i>	mitotic spindle positioning	0.321	1.38E-03
<i>Gm9913</i>	predicted gene 9913	0.321	2.36E-03
<i>Pydc3</i>	interferon activated gene 208	0.319	1.17E-04
<i>Rtp4</i>	receptor transporter protein 4	0.318	1.61E-06
<i>Trex1</i>	three prime repair exonuclease 1	0.318	6.14E-05
<i>Rasl11a</i>	RAS-like, family 11, member A	0.314	4.30E-04
<i>Pydc4</i>	interferon activated gene 213	0.313	3.36E-04
<i>Col11a2</i>	collagen, type XI, alpha 2	0.313	3.25E-03
<i>Pira2</i>	paired-Ig-like receptor A2	0.31	7.69E-04
<i>Galnt6</i>	UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6	0.308	2.52E-03
<i>Tnfsf13</i>	tumor necrosis factor (ligand) superfamily, member 13	0.307	6.07E-03
<i>Slamf7</i>	SLAM family member 7	0.305	3.92E-03
<i>Gm10146</i>	predicted gene 10146	0.305	8.98E-03
<i>Enho</i>	energy homeostasis associated	0.305	8.29E-03
<i>Cpt1a</i>	carnitine palmitoyltransferase 1A	0.302	5.73E-04

FC: Fold change (Log10); \*Source: <https://www.ncbi.nlm.nih.gov/gene/>